Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc news (Ticker: KNSA), a resource for investors and traders seeking the latest updates and insights on Kiniksa Pharmaceuticals International, plc stock.
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) is a commercial-stage biopharmaceutical company dedicated to discovering, acquiring, developing, and commercializing therapeutic medicines for patients with debilitating diseases that have significant unmet medical needs. Headquartered in Hamilton, Bermuda, Kiniksa is at the forefront of developing immune-modulating assets aimed at addressing a spectrum of cardiovascular and autoimmune conditions.
The company’s clinical-stage product candidates include:
- ARCALYST (rilonacept): The first and only FDA-approved therapy for recurrent pericarditis, a debilitating inflammatory cardiovascular disease. ARCALYST is also approved for cryopyrin-associated periodic syndromes (CAPS) and deficiency of IL-1 receptor antagonist (DIRA).
- Mavrilimumab: An investigational monoclonal antibody targeting the GM-CSF receptor, currently being evaluated for its potential in treating giant cell arteritis and other rare cardiovascular diseases.
- Vixarelimab: An investigational monoclonal antibody inhibitor of signaling through OSMRβ.
- Abiprubart (formerly KPL-404): A humanized monoclonal antibody designed to inhibit the CD40-CD154 interaction, aimed at treating autoimmune diseases such as rheumatoid arthritis and Sjogren’s Disease.
Kiniksa’s robust pipeline is supported by significant financial strength. The company reported strong revenue growth with ARCALYST, achieving net product revenue of approximately $233.1 million in 2023, a 90% year-over-year increase. This financial performance provides a solid foundation for future investments in both commercial and clinical development projects.
Recent news highlights Kiniksa’s progress:
- In July 2023, Kiniksa announced plans to raise its 2023 ARCALYST sales guidance to between $220 million and $230 million, citing increased prescriber adoption and patient enrollments.
- In October 2023, the company reported third-quarter financial results and the completion of enrollment in the third cohort of the Phase 2 trial of KPL-404 in rheumatoid arthritis, with data expected in the first quarter of 2024.
- In February 2024, Kiniksa announced its plans to initiate a Phase 2b trial of abiprubart in Sjogren’s Disease in the second half of 2024, supported by robust ARCALYST revenue growth and a strong cash position.
For more information about Kiniksa and its pipeline, visit www.kiniksa.com.
Kiniksa Pharmaceuticals reported Q4 2022 net product revenue of ARCALYST at $39.9 million and full-year revenue of $122.5 million. For 2023, net product revenue is expected between $190 million and $205 million, indicating over 60% growth from 2022. The average therapy duration was approximately 18 months, with a strong payer approval rate exceeding 90%. Kiniksa maintains cash reserves to support operations through at least 2025. Financially, total revenue for 2022 reached $220.2 million with a net income of $183.4 million, boosted by a significant tax benefit.
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) will host a conference call on February 28, 2023, at 8:30 a.m. ET, to discuss its fourth quarter and full-year 2022 financial results and recent portfolio execution.
The call will be accessible via a live webcast on Kiniksa's website. Telephone participants must register to receive dial-in details. A replay will be available approximately 48 hours post-event. Kiniksa focuses on developing therapeutic medicines for critical unmet medical needs, with assets like ARCALYST and KPL-404 targeting cardiovascular and autoimmune conditions.
Kiniksa Pharmaceuticals (KNSA) reported net product revenue of $39.9 million for Q4 2022 and $122.5 million for full-year 2022. The company's cash reserves of $190.4 million are projected to support operations through 2025. Kiniksa has enrolled 2 of 3 cohorts in the Phase 2 trial of KPL-404 for rheumatoid arthritis, with results expected in 1H 2024. The company aims to grow its cardiovascular franchise through ARCALYST sales and collaborative agreements for mavrilimumab, indicating a focus on strategic portfolio optimization.
FAQ
What is the current stock price of Kiniksa Pharmaceuticals International, plc (KNSA)?
What is the market cap of Kiniksa Pharmaceuticals International, plc (KNSA)?
What is Kiniksa Pharmaceuticals' primary focus?
What are the key products in Kiniksa's pipeline?
What recent achievements has Kiniksa Pharmaceuticals reported?
What is ARCALYST used for?
When was Kiniksa's latest financial report released?
What is the expected revenue for ARCALYST in 2024?
What is abiprubart (KPL-404) targeting?
What are some of the conditions Kiniksa is targeting with its therapies?
Where can I find more information about Kiniksa Pharmaceuticals?
Who should be contacted for investor and media inquiries?
